Updates are available Correction dated 2023-06-06
Click to view Correction: https://doi.org/10.1038/s42256-023-00681-x
-
Authors
Ren, Tao http://orcid.org/0000-0002-6486-7338
Chen, Canping http://orcid.org/0000-0003-4021-8592
Danilov, Alexey V. http://orcid.org/0000-0003-4461-0970
Liu, Susan http://orcid.org/0000-0002-1784-6059
Guan, Xiangnan
Du, Shunyi
Wu, Xiwei
Sherman, Mara H. http://orcid.org/0000-0001-7826-3888
Spellman, Paul T. http://orcid.org/0000-0002-4810-0022
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Adey, Andrew C. http://orcid.org/0000-0001-7648-8717
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Wu, Ling-Yun http://orcid.org/0000-0001-9487-0215
Xia, Zheng http://orcid.org/0000-0003-3364-8324
- License Information
-
More Information
Article History
Received: 22 September 2022
Accepted: 6 April 2023
First Online: 8 May 2023
Change Date: 6 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42256-023-00681-x
Competing interests
: A.V.D. has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, Incyte, Lilly Oncology, Morphposys, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology. X.G. is a Genentech employee and Roche shareholder. G.B.M. is SAB/Consultant for AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine and Zentalis Pharmaceuticals; stock/options/financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda and Turbine; licenced technology: HRD assay to Myriad Genetics, and DSP patents with Nanostring. L.M.C. provides consulting services for Cell Signaling Technologies, AbbVie, the Susan G Komen Foundation and Shasqi, received reagent and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZelBio Inc., Hibercell Inc. and Acerta Pharma, and participates in advisory boards for Pharmacyclics, Syndax, Carisma, Verseau, CytomX, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, Zymeworks, Genenta Sciences, Pio Therapeutics Pty Ltd, PDX Pharmaceuticals, the AstraZeneca Partner of Choice Network, the Lustgarten Foundation and the NIH/NCI-Frederick National Laboratory Advisory Committee. The remaining authors declare no competing interests.
